Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis

share with twitter share with LinkedIn share with facebook
share via e-mail
08/12/2019 | 09:08am EDT

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for SIRTURO(bedaquiline) tablets as part of combination therapy in pediatric patients - those over the age of 12 and younger than 18 and weighing at least 66 pounds (30 kilograms) - with pulmonary multidrug-resistant tuberculosis (MDR-TB), when an effective treatment regimen cannot otherwise be provided.

Approved under the FDA's accelerated approval pathway based on time to sputum culture conversion, bedaquiline can now be used as part of combination therapy for eligible MDR-TB patients aged 12 years and over in the U.S. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.

The FDA approval marks the first regulatory milestone as part of the company's global pediatric research and development (R&D) program for bedaquiline, with additional global regulatory filings planned. Further research is ongoing in children younger than 12 years of age using a pediatric formulation of bedaquiline.

TB is the world's deadliest infectious disease, claiming 1.6 million lives every year - more than HIV and malaria combined.i While TB often affects adults in their most productive years, all age groups are at risk. In 2017, an estimated 1 million children became ill with TB and 230,000 children died of the disease[i], underscoring the urgent need for effective pediatric TB treatments. Approximately 95% of childhood deaths from TB occur in Asia and sub-Saharan Africa.[ii]

'We are proud of what today's approval means for adolescent patients in the U.S., and we are hopeful about the future of our pediatric R&D program,' said Paul Stoffels, M.D., Vice Chair of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. 'Despite being a major global health issue, TB lacks the attention and resources it requires - and the issue of TB in children is even more neglected. At Johnson & Johnson, we are committed to developing solutions that address the needs of all TB patients, including the youngest and most vulnerable.'

Today's U.S. FDA approval is supported by evidence from a single-arm, open-label, Phase 2 study that enrolled 15 pediatric patients with confirmed or probable MDR-TB infection. The patients were treated with the recommended dosage of bedaquiline for 24 weeks in combination with a background regimen. Bedaquiline was administered on the same schedule as it is for adults: 400 mg once daily for the first two weeks and 200 mg three times per week for the following 22 weeks. In the subset of patients with culture positive pulmonary MDR-TB at baseline, treatment with bedaquiline resulted in conversion to a negative culture in 6/8 (75%) patients at Week 24.

The most common adverse drug reactions were arthralgia in 6/15 (40%) patients, nausea in 2/15 (13%) patients and abdominal pain in 2/15 (13%) patients. Among the 15 patients, no deaths occurred during treatment with bedaquiline. Observed laboratory abnormalities were comparable to those in adults.

'In the past, MDR-TB was a diagnosis that left patients with few options. But fortunately, new treatments and other tools have brought a renewed sense of hope for patients,' said Jaak Peeters, Global Head, Johnson & Johnson Global Public Health, Janssen-Cilag GmBH. 'At Johnson & Johnson, we won't rest until we have optimized and helped to deliver effective MDR-TB treatment to patients of every age, wherever they may be.'

About the Bedaquiline Global Pediatric Development Program

As part of the company's commitment to the continued clinical development of bedaquiline, Janssen is conducting a Phase 2 sequential pediatric pharmacokinetic and safety study, C211, with four cohorts of patients in different age groups. The U.S. FDA approval of the use of bedaquiline in adolescents (12 to 30 kg) is supported by the results from Cohort 1 of the study. Cohort 2 of the study (5 to

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
09/19JOHNSON & JOHNSON : Janssen to Highlight Depth of Prostate Cancer and Solid Tumo..
09/19JOHNSON & JOHNSON : U.S. FDA Approves Supplemental New Drug Application (sNDA) f..
09/18JOHNSON & JOHNSON : to Host Investor Conference Call on Third Quarter Results
09/18THE LATEST : J&J company says it will fight WVa mesh lawsuit
09/18JOHNSON & JOHNSON : - U.S. FDA Approves Supplemental New Drug Application for ER..
09/17JOHNSON & JOHNSON : Janssen to Highlight Depth of Prostate Cancer and Solid Tumo..
09/17JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA Seeking First-in-Cla..
09/16JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA Seeking First-in-Cla..
09/16JOHNSON & JOHNSON : Vision Introduces TECNIS Synergy™ IOL, a Continuous-Ra..
09/16JOHNSON & JOHNSON : - New DARZALEX Data from GRIFFIN Study Show High Response Ra..
More news
Financials (USD)
Sales 2019 81 612 M
EBIT 2019 25 394 M
Net income 2019 19 218 M
Debt 2019 5 560 M
Yield 2019 2,85%
P/E ratio 2019 18,9x
P/E ratio 2020 16,9x
EV / Sales2019 4,33x
EV / Sales2020 4,07x
Capitalization 347 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 21
Average target price 148,75  $
Last Close Price 131,65  $
Spread / Highest target 28,4%
Spread / Average Target 13,0%
Spread / Lowest Target -5,81%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.82%347 446
ROCHE HOLDING LTD.16.27%245 289
MERCK AND COMPANY11.45%218 042
PFIZER-15.95%202 934
NOVARTIS15.60%199 009
NOVO NORDISK AS17.30%124 981